NASDAQ$LUNG
Pulmonx Corporation · Q1 2026 earnings
Q1 2026 earnings · · Investor relations
Briefing
Pulmonx reported Q1 2026 revenue of $20.6M and a net loss of $13.7M, or $0.33 per share.
For the quarter ended March 31, 2026, Pulmonx generated revenue of $20.6 million versus $22.5 million on Zephyr valve procedures. Net loss was $13.7 million ($0.33 per share) compared with $14.4 million as operating expenses remained elevated for commercial and clinical support.
- Revenue $20.6M; net loss $13.7M.
- EPS $(0.33); operating loss ~$13.0M.
- Zephyr endobronchial valve adoption in COPD/emphysema.
- Cash runway and reimbursement expansion key themes.
Headline financials
Revenue & EPS history
Pulmonx · Revenue · Quarterly
$20.6M
Forward guidance
Med-tech commercialization; outlook tied to procedure growth and payer coverage rather than EPS guidance.
Tailwinds
- Loss narrowed slightly year over year.
- Established commercial product in bronchoscopic lung volume reduction.
Headwinds
- Revenue down modestly YoY.
- Operating losses until scale improves.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2026
-3.4%
Avg return
Earnings day
-4.1%
Avg return
5 days after
-5.3%
Avg return
30 days after
42%
10 / 24 earnings
Positive
+32.2%
Q4 2024
Best reaction
-64.7%
Q3 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -1.5% | -6.7% | +12.6% | |
| Q4 2025 | +0.6% | -6.1% | -28.2% | |
| Q3 2025 | -18.9% | -28.6% | +29.1% | |
| Q1 2025 | -21.9% | -28.8% | -29.6% | |
| Q4 2024 | +32.2% | +30.7% | +17.0% | |
| Q3 2024 | -7.7% | +5.2% | -4.7% | |
| Q2 2024 | -8.1% | -15.4% | +3.7% | |
| Q1 2024 | +23.3% | +21.9% | -4.7% | |
| Q4 2023 | -17.7% | -27.9% | -36.1% | |
| Q3 2023 | +6.9% | +20.7% | +34.2% | |
| Q2 2023 | -4.1% | -8.0% | -26.0% | |
| Q1 2023 | +1.1% | -0.2% | -1.5% | |
| Q4 2022 | +20.8% | +26.0% | +27.1% | |
| Q3 2022 | -64.7% | -61.1% | -52.3% | |
| Q2 2022 | +9.2% | +19.9% | +5.7% | |
| Q1 2022 | +0.6% | -23.6% | -23.9% | |
| Q4 2021 | -6.9% | -2.5% | -12.5% | |
| Q3 2021 | +7.1% | +12.6% | -23.7% | |
| Q2 2020 | -7.6% | -10.9% | -1.6% | |
| Q2 2021 | +0.1% | +6.0% | +3.3% | |
| Q1 2020 | -5.8% | -5.3% | +9.9% | |
| Q1 2021 | -8.7% | -9.6% | -10.3% | |
| Q4 2020 | -4.1% | -3.4% | -20.2% | |
| Q3 2020 | -4.9% | -3.4% | +5.6% | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro